GET DAILY SIGNALSAclaris Therapeutics (ACRS) Q3 2026 Results: Pipeline Progress Amid a Wider Net Loss
Key Takeaways
- Aclaris Therapeutics (ACRS) reported a third quarter 2026 net loss of $18.5 million, widening from $14.6 million in the same period a year earlier.
- GAAP loss per share came in at $0.12, beating the consensus estimate of a $0.16 loss.
- Revenue of $1.48 million topped analyst expectations, though it declined from $3.3 million a year ago due to a prior-year Sun Pharma milestone.
- Management highlighted positive Phase 1b proof-of-concept data for ATI-052 in atopic dermatitis and asthma as the quarter's headline clinical catalyst.
- The company reaffirmed cash guidance, extending its runway through the first half of 2029 following an October equity offering.
- For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
- Discover automated trading ideas by exploring Trending AI Robots.
Why Quarterly Results Matter for a Clinical-Stage Biotech
As a clinical-stage biopharmaceutical company, Aclaris Therapeutics generates modest revenue while its value story rests almost entirely on the progress of its immuno-inflammatory drug pipeline. Quarterly earnings therefore serve less as a test of profitability and more as a checkpoint on clinical execution, spending discipline, and cash runway. Heading into this report, investors were focused on whether ATI-052 could validate its promise in atopic dermatitis and asthma, and whether the company's balance sheet could support a growing slate of mid-stage trials. With multiple Phase 2 readouts and regulatory filings scheduled across late 2026 and 2027, this quarter offered a critical look at how well Aclaris is converting its earlier-stage programs into late-stage catalysts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
Aclaris Therapeutics reported a net loss of $18.5 million for the third quarter of 2026, compared with $14.6 million a year earlier. GAAP loss per share was $0.12, narrower than the consensus estimate of a $0.16 loss. Total revenue reached $1.48 million, above the roughly $1.2 million analysts had expected, but down from $3.3 million in the prior-year period. The revenue decline primarily reflected a sales milestone recognized under the Sun Pharma license agreement in the third quarter of 2025.
Research and development (R&D) expenses rose to $16.1 million from $13.0 million, driven by ATI-052 manufacturing and clinical costs plus ATI-9494 development. General and administrative (G&A) expenses increased to $6.0 million from $4.9 million. For the nine months ended September 30, 2026, revenue was $5.1 million and the net loss was $59.8 million, compared with $6.5 million and $45.1 million in the prior-year period.
Market Reaction and Investor Sentiment
Investor attention around this report centered on the clinical narrative rather than the bottom line. The positive primary analysis from ATI-052's Phase 1b proof-of-concept trials in atopic dermatitis and asthma reinforced confidence in the company's antibody platform, while management's decision to prioritize a Phase 2b program in eosinophilic esophagitis signaled disciplined capital allocation. At the same time, the quarter reflected rising R&D spend and a wider net loss, and a recent discounted equity offering introduced dilution concerns. Sentiment remained balanced between enthusiasm for near-term data catalysts and caution around the cost of advancing a multi-program pipeline.
Forward Outlook and Key Factors to Monitor
Looking ahead, Aclaris has packed the coming months with clinical and regulatory milestones that investors will be watching closely. The Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis is expected to deliver top-line results in the fourth quarter of 2026, a readout that could meaningfully shape sentiment around the antibody franchise.
In parallel, the company expects to initiate a Phase 2b trial of modzatinib (ATI-2138) in lichen planus during the fourth quarter of 2026, with first site activation anticipated in November. The filing of an Investigational New Drug (IND) application for ATI-9494, an oral dual ITK/TXK inhibitor, also remains on track for the fourth quarter. These catalysts position late 2026 as a pivotal window for the pipeline.
On the financial side, Aclaris reported $204.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026. Combined with a $50 million October offering, management believes the runway extends through the first half of 2029. Investors will continue to monitor R&D expense growth, future financing decisions, and whether upcoming data readouts justify the company's expanding clinical investment. From what I see, the upcoming readouts will be the real test of execution.
Using AI Tools in My Research Process
When analyzing pipeline-focused names like Aclaris, I find it helpful to run quick comparisons across peers and technical setups. Tickeron’s AI Screener lets me apply custom filters for volatility, fundamentals, and AI signals in one place, which saves time when cross-checking how this stock stacks up against similar biotech names before digging deeper into the clinical data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ACRS turns positive, indicating new upward trend
ACRS saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 84 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACRS's RSI Oscillator exited the oversold zone, 22 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ACRS just turned positive on October 21, 2026. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
Following a +5.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in 222 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ACRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 62 cases where ACRS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ACRS entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.608) is normal, around the industry mean (3.482). P/E Ratio (-6.724) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (83.333) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ACRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of novel dermatological therapies
Industry Biotechnology
Advertisement